Cetuximab Scfv-Modified 5-Fu Loaded Chitosan Nanoparticles: “A Novel Therapeutic Platform.”

Cetuximab Scfv-Modified 5-Fu Loaded Chitosan Nanoparticles: “A Novel Therapeutic Platform.” Publisher Pubmed

Jalalvand M¹ ; Esmaeili F² ; Falahzadeh K¹ ; Mazloumi M¹ ; Bayat E⁴ ; Zandsalimi F⁵ ; Talebkhan Y⁴ ; Nematollahi L⁴

Show Affiliations

1. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
4. Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
5. Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Current Pharmaceutical Biotechnology Published:2025

Abstract

Background: Colorectal cancer [CRC] is among the most fatal types of cancer. An active targeting delivery system that specifically interacts with CRC cells could improve the therapy's outcomes. Herein, Cetuximab single-chain fragment variable antibody [scFv] fragments were conjugated to the surface of 5-FU encapsulated chitosan nanoparticles [CS NPs] to develop an effective therapeutic platform [scFv-CS/5-FU NPs]. Method: CS/5-FU NPs were synthesized using a special fluidic system. Encapsulation efficiency [EE], loading capacity [LC], and the drug release profile of the particles were determined. scFv fragments were produced recombinantly and tailored on the surface of CS/5-FU NPs. The physicochemical features of scFv-CS/5-FU NPs were also characterized. MTT and flow cytometry assay investigated the toxicity effect of scFv-CS/5-FU NPs on the HCT116 cell line. Results: CS/5-FU NPs had a homogenous spherical shape. They possessed sustainable drug-release behavior. The produced scFv-CS/5-FU NPs were also spherical. scFv-CS/5-FU NPs significantly decreased the viability of cancerous cells in a dose-dependent manner and induced apoptosis in 97.97% of targeted cells. Conclusion: scFv-CS/5-FU NPs showed remarkable anti-CRC activity. This novel targeting delivery system reduced the effective dose of 5-FU which is of vital importance to decrease the devastating side effects of chemotherapy. © 2024 Bentham Science Publishers.

2. Nano-Particles’ Benefits for Colon Cancer Effective Therapy: A Review of Recent Advancements and Clinical Trials, International Journal of Polymeric Materials and Polymeric Biomaterials (2024)

3. Nanostructures for Site-Specific Delivery of Oxaliplatin Cancer Therapy: Versatile Nanoplatforms in Synergistic Cancer Therapy, Translational Oncology (2024)

Experts (# of related papers)

View all Related Experts

Babak Negahdari (1)

Reza Faridi Majidi (1)

Style	Citing Format
MLA	Jalalvand M, et al.. "Cetuximab Scfv-Modified 5-Fu Loaded Chitosan Nanoparticles: “A Novel Therapeutic Platform.”." Current Pharmaceutical Biotechnology, vol. , no. , 2025, pp. -.
APA	Jalalvand M, Esmaeili F, Falahzadeh K, Mazloumi M, Bayat E, Zandsalimi F, Talebkhan Y, Nematollahi L (2025). Cetuximab Scfv-Modified 5-Fu Loaded Chitosan Nanoparticles: “A Novel Therapeutic Platform.”. Current Pharmaceutical Biotechnology, (), -.
Chicago	Jalalvand M, Esmaeili F, Falahzadeh K, Mazloumi M, Bayat E, Zandsalimi F, Talebkhan Y, Nematollahi L. "Cetuximab Scfv-Modified 5-Fu Loaded Chitosan Nanoparticles: “A Novel Therapeutic Platform.”." Current Pharmaceutical Biotechnology , no. (2025): -.
Harvard	Jalalvand M et al. (2025) 'Cetuximab Scfv-Modified 5-Fu Loaded Chitosan Nanoparticles: “A Novel Therapeutic Platform.”', Current Pharmaceutical Biotechnology, (), pp. -.
Vancouver	Jalalvand M, Esmaeili F, Falahzadeh K, Mazloumi M, Bayat E, Zandsalimi F, et al.. Cetuximab Scfv-Modified 5-Fu Loaded Chitosan Nanoparticles: “A Novel Therapeutic Platform.”. Current Pharmaceutical Biotechnology. 2025;():-.
BibTex	@article{ author = {Jalalvand M and Esmaeili F and Falahzadeh K and Mazloumi M and Bayat E and Zandsalimi F and Talebkhan Y and Nematollahi L}, title = {Cetuximab Scfv-Modified 5-Fu Loaded Chitosan Nanoparticles: “A Novel Therapeutic Platform.”}, journal = {Current Pharmaceutical Biotechnology}, volume = {}, number = {}, pages = {-}, year = {2025} }
RIS	TY - JOUR AU - Jalalvand M AU - Esmaeili F AU - Falahzadeh K AU - Mazloumi M AU - Bayat E AU - Zandsalimi F AU - Talebkhan Y AU - Nematollahi L TI - Cetuximab Scfv-Modified 5-Fu Loaded Chitosan Nanoparticles: “A Novel Therapeutic Platform.” JO - Current Pharmaceutical Biotechnology VL - IS - SP - EP - PY - 2025 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract